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Background/Purpose: The emergence of multidrug-resistant Neisseria gonorrhoeae is a great challenge in
controlling gonorrhea. This study was conducted to survey the prevalence of molecular mechanisms of 
antimicrobial resistance among 45 clinical isolates of N. gonorrhoeae collected at a university hospital 
in Southern Taiwan during 1999–2004.
Methods: Mutations in mtrR loci and quinolone-resistance-determining regions (QRDRs) were examined
by gene sequencing. Polymerase chain reactions with specific primers were performed to detect ermA,
ermB, ermC, and ermF. Serogroups and serovars were determined by commercial kits.
Results: The percentage of multidrug resistance, that is, resistance to penicillin, tetracycline, erythromycin,
and ciprofloxacin, among the 45 isolates was 40%. Ceftriaxone and spectinomycin were active against all
isolates in vitro. The frequency of mutations in the QRDR and mtrR promoter was 82.2% and 93.3%, re-
spectively. Eighty-two percent of the isolates carried mutations both in the QRDR and mtrR loci. Of nine
mutation profiles with QRDR mutations (n = 37), gyrA-Ser91Phe/gyrA-Asp95Gly/parC-Ser87Arg was the
most common type (56.8%). Acquired genes for rRNA methylase were detected in 11 isolates (10 ermB
and 1 ermA). Twenty-seven serovars were identified and all belonged to serogroup B, which suggested that
multiple clones of N. gonorrhoeae were circulating in the community in the Tainan area.
Conclusion: The high prevalence of multidrug resistance caused by varied resistance mechanisms 
in N. gonorrhoeae limits the drug choice. Ongoing surveillance of antimicrobial resistance and discovery 
of new effective antibiotic therapy are warranted in endemic areas. [J Formos Med Assoc 2010;109(2):
120–127]
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Appropriate antibiotic treatment is an important
element in gonorrhea control. However, resistance
to multiple classes of antimicrobial agents in
Neisseria gonorrhoeae has increased worldwide in
recent decades.1,2 In the United States, previously
effective oral antibiotics, fluoroquinolones and
azithromycin, have not been the recommended
drugs for gonorrhea because of concerns about
drug resistance and clinical treatment failure.3 The
emergence of multidrug-resistant N. gonorrhoeae
has limited the drug choice for gonorrhea and
has become a great challenge in public health.
Thus, further screening of drug-resistance mecha-
nisms, especially in multidrug-resistant strains
isolated from endemic areas, should provide a
more in-depth understanding of resistance trends
and possibly affect drug recommendations.
Several drug-resistance mechanisms have been
determined in N. gonorrhoeae. Mutations in the
quinolone-resistance-determining region (QRDR)
of DNA gyrase A (gyrA) and parC-encoded topoi-
somerase IV subunits (parC) mediate resistance to
fluoroquinolones. Moreover, multiple mutations
in the QRDR result in high-level fluoroquino-
lone resistance.4–6 The methylase encoded by erm
genes can block macrolide binding by modifying
rRNA and increasing macrolide–lincosamide–
streptogramin B resistance in N. gonorrhoeae.7,8
Another resistance mechanism, the multiple trans-
ferable resistance (mtr) efflux pump, can mediate
resistance to triton X, crystal violet, erythromy-
cin, and fusidic acid.9,10 The genetic organization
of the mtr system consists of three mtrCDE genes,
which are regulated negatively by the products of
divergent but adjacent mtrR genes.11 Moreover,
several studies have shown that mutations in the
mtrR promoter decrease expression of mtrR, and
lead to overexpression of the mtr efflux pump.
Consequently, the gonococcal strains with such 
a mutation demonstrate resistance to erythro-
mycin and azithromycin.12–15 It is also possible
that gonococci can have different drug-resistance
mechanisms simultaneously. Dewi et al reported
that simultaneous mutations in the QRDR and
the mtrRCDE efflux system were detected in 
71% of 131 N. gonorrhoeae strains in Japan.16
Consequently, the presence of different resistance
mechanisms impedes drug choice and becomes
a great challenge in controlling gonorrhea in an
endemic area.
Without exception, N. gonorrhoeae strains re-
sistant to penicillins, tetracyclines, macrolides, and
fluoroquinolones have been noted in Northern
Taiwan in recent decades.17,18 Notably, a high
prevalence of ciprofloxacin resistance related to
chromosomal mutations in the QRDR among 
N. gonorrhoeae strains has limited the use of fluo-
roquinolones in this area.18 Consequently, current
treatment guidelines for gonorrhea in Taiwan in-
clude only intravenous or intramuscular ceftriax-
one and spectinomycin.19
A large-scale study of antimicrobial resistance
in N. gonorrhoeae in Taiwan is still lacking. In addi-
tion, we have found previously that drug-resistant
N. gonorrhoeae isolates and ineffective antibiotic
therapy are common in the hospital (unpublished
data). Therefore, in the present study, we investi-
gated the prevalence of various drug-resistance
mechanisms, including mutations in the QRDR
and mtrR loci, as well as the presence of erm genes
in the N. gonorrhoeae isolates at a tertiary hospital
in Southern Taiwan.
Materials and Methods
Bacterial isolates
All N. gonorrhoeae clinical isolates collected from
90 patients between 1999 and 2004 were pre-
served at –70°C. All samples were subcultured
on chocolate agar plates for 24 hours before 
further experiments. Medical records of all 90
patients were reviewed for demographic data
and clinical presentations.
Antimicrobial susceptibility
For antimicrobial susceptibility testing, gonococcal
isolates were subcultured on gonococcus (GC)
medium (BBL, Cockeysville, MD, USA) and incu-
bated for 18–24 hours in a 36°C incubator with
5% CO2. Minimal inhibitory concentrations
(MICs) of penicillin, tetracycline, azithromycin,
QRDR and mtrR mutations in Neisseria gonorrhoeae
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ceftriaxone, cefixime, ciprofloxacin, and spectino-
mycin for N. gonorrhoeae were determined by Etest
(AB Biodisk, Solna, Sweden). The antimicrobial
susceptibility was categorized by the breakpoint
criteria proposed by the Clinical and Laboratory
Standards Institute.20 Although the breakpoint for
azithromycin resistance has not been determined, a
consensus concentration of ≥ 1 μg/mL was used to
indicate resistance to azithromycin.21 The isolates
were grouped sequentially into mutually exclusive
categories according to the National Committee
for Clinical Laboratory Standards guidelines as
follows:22 penicillinase-producing N. gonorrhoeae
(PPNG); plasmid-mediated tetracycline-resistant
N. gonorrhoeae (TRNG); PPNG-TRNG; chromoso-
mally mediated penicillin-resistant N. gonorrhoeae;
chromosomally mediated tetracycline-resistant
N. gonorrhoeae; and chromosomally mediated re-
sistance to both penicillin and tetracycline. The
production of penicillinase was measured by the
cefinase test (Becton Dickinson BBL, Sparks, USA).
N. gonorrhoeae ATCC 49226 was included as a
control.
Detection of acquired genes and mutations
that mediate macrolide and fluoroquinolone
resistance
Genetic components responsible for erythromy-
cin resistance, including genes that encode rRNA
methylases (ermA, ermB, ermC, and ermF), were de-
tected by polymerase chain reaction (PCR). PCR
primers and conditions for the detection of these
genes have been described previously.7,8 N. 
gonorrhoeae isolates were screened for any muta-
tion within the mtrR promoter, as described previ-
ously.23 Gene sequences of QRDR, gyrA and parC
were investigated by the primers and amplifica-
tion conditions used by Tanaka et al.6 The PCR
amplification products were sequenced (Applied
Biosystems, Foster City, CA, USA). Gene sequences
were compared with quinolone-susceptible strain
FA-19 that has been described by Belland et al.23
Serogroup and serovar analysis
Serogroupings WI and WII/WIII of N. gonor-
rhoeae isolates were examined by the Phadebact
Monoclonal GC Test, and serovars by the Phade-
bact GC Serovar Test (Boule Diagnostics AB,
Huddinge, Sweden). Serogroups were determined
by WI (IA) and WII/III (IB) reagents, which con-
tained monoclonal antibodies to protein IA and
IB, respectively. Each strain was examined with a
set of five antibodies specific to protein IA (Ao, Ar,
As, At, and Av), and nine antibodies specific to
protein IB (Bo, Bp, Br, Bs, Bt, Bu, Bv, Bx, and By).
All procedures were performed following the man-
ufacturer’s instructions.
Statistical analysis
Data analysis was analyzed using SPSS version
12.0 (SPSS Inc., Chicago, IL, USA). Continuous
variables, expressed as mean ± standard deviation,
were compared by the nonparametric Mann–
Whitney U test or student’s t test. Categorical vari-
ables were compared using the χ2 test. A p value
<0.05 was considered to be statistically significant.
Results
Study of patients with study isolates
Only 45 of 90 stored isolates were viable and avail-
able for investigation. To exclude potential selec-
tion bias, the clinical characteristics of the other
45 patients whose isolates were not available for
study (the exclusion population) were compared
with those with viable isolates (the inclusion
population). The major clinical manifestation in
both populations was urethritis [36 (77.8%) in
the inclusion population and 40 (88.9%) in the
exclusion population, p = 0.25]. Among the inclu-
sion and exclusion populations, there was no sig-
nificant difference in the number of the visits to
outpatient clinics (2.9 ± 1.4 vs. 2.9 ± 1.4, p = 0.95),
age (26.1 ± 8.5 vs. 29.2 ± 10.8 years, p = 0.13), and
male-to-female ratio (4 vs. 5, p = 0.25).
Antimicrobial resistance for N. gonorrhoeae
isolates
Susceptibility to various antimicrobial agents is
shown in Table 1. No clinical isolate was suscep-
tible to penicillin. The proportion of N. gonorrhoeae
QRDR and mtrR mutations in Neisseria gonorrhoeae
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isolates susceptible to tetracycline, erythromycin,
and ciprofloxacin was low (4.4%, 11.1%, and
17.8%, respectively). Multidrug resistance (i.e. re-
sistance to penicillin, tetracycline, erythromycin,
and ciprofloxacin) was noted in 40% of all isolates.
There were 23 (51.1%) isolates with high-level
resistance to ciprofloxacin (i.e. MIC ≥ 32 μg/mL).
All clinical isolates were susceptible to ceftriaxone
and spectinomycin. According to recommended
criteria,21 universal susceptibility to azithromycin
was observed.
Five (11.1%) and three (6.7%) isolates were
PPNG and PPNG-TRNG, respectively. Moreover, all
of these isolates that produced penicillinase were
highly resistant to penicillin (MIC ≥ 4 μg/mL).
Chromosomally mediated resistance to penicillin,
tetracycline, and both was found in 14 (31.1%),
one (2.2%), and five (11.1%) isolates, respectively.
Four (8.9%) TRNG strains, not including PPNG-
TRNG, were identified during the study period.
The remaining 13 strains did not have any type
of resistance to penicillin and tetracycline.
Mutation in mtrR loci
In mtrR promoter genes, a single A/T base pair
(bp) deletion was observed in 93.3% (42/45) of
isolates. This 1-bp adenine deletion was located
within a 13-bp inverted repeat between –10 and
–35 hexamers, as compared with a wild-type strain
(GenBank database accession number Z25797).
Two mutation profiles in mtrR, Gly55Asp
(G55D, 6 isolates) and Ala49Thr (A49T, 4 iso-
lates), were discovered in 10 isolates. Nine of them
possessed the 1-bp adenine deletion in the mtrR
promoter. Moreover, there was a null mutation
observed at codon 39, 40, or 57.
Mutations in gyrA and parC genes
The association between MICs for ciprofloxacin
and QRDR mutations in 45 isolates is summarized
in Table 2. Thirty-seven (82.2%) isolates had mu-
tation in the QRDR, including mutations in gyrA
(n = 37, 82.2%), and parC (n = 29, 64.4%). All the
37 strains had a concurrent 1-bp deletion in the
mtrR locus. The MIC for ciprofloxacin for strains
(n = 3) without any mutations was ≤ 0.006 μg/mL.
The presence of a mutation in mtrR slightly in-
creased the MIC to 0.004–0.012μg/mL. In contrast,
some isolates with QRDR mutations demon-
strated high levels of ciprofloxacin resistance (MIC
> 32 μg/mL). The MIC level of ciprofloxacin in-
creased with the number of mutations in the
QRDR. Among 35 ciprofloxacin-resistant isolates,
29 contained three amino acid substitutions, and
six had two substitutions in the QRDR.
There were nine QRDR mutation profiles, 
including Ser91Phe, Asp95Gly, Asp95Ala, and
Asp95Asn in gyrA; and Ser87Asn, Ser87Arg, and
Glu91Ala in parC. All strains with three QRDR
alterations were characteristic of two mutations
in gyrA and one in parC. GyrA-Ser91Phe/gyrA-
Asp95Gly/parC-Ser87Arg was the predominate
Table 1. In vitro susceptibility to antimicrobial agents of 45 clinical Neisseria gonorrhoeae isolates
Antimicrobial MIC (μg/mL)* Isolate
†
agents Range 50% 90% Susceptible Intermediate Resistant
Penicillin 0.190 to >32 2.0 > 32 0 (0) 13 (28.9) 32 (71.1)
Tetracycline 0.090–64 1.5 32 2 (4.4) 16 (35.6) 27 (60.0)
Ciprofloxacin 0.002 to > 32 > 32 > 32 8 (17.8) 2 (4.4) 35 (77.8)
Erythromycin 0.016–6 1.0 2.0 5 (11.1) 12 (26.7) 28 (62.2)
Azithromycin‡ 0.016–0.500 0.125 0.250 45 (100) 0 (0) 0 (0)
Cefixime 0.016–0.064 0.023 0.032 45 (100) 0 (0) 0 (0)
Ceftriaxone 0.016–0.094 0.032 0.047 45 (100) 0 (0) 0 (0)
Spectinomycin 4–24 8 12 45 (100) 0 (0) 0 (0)
*Criteria for all agents but azithromycin followed those recommended by the Clinical and Laboratory Standards Institute; †data pre-
sented as n (%); ‡critical MIC ≥ 1mg/mL for azithromycin recommended by Neisseria Reference Laboratory at the Centers for Disease
Control, Atlanta, GA, USA. MIC = minimum inhibitory concentration.
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profile (21/37, 56.8%). Among them, 19 (90.5%)
had high-level resistance to ciprofloxacin (MIC
≥ 32 μg/mL).
Genes associated with erythromycin resistance
A total of 35 isolates were resistant to erythro-
mycin, and the rest had intermediate resistance.
Acquired genes for rRNA methylase genes were
detected in 12 isolates (11 ermB and 1 ermA; eryth-
romycin MIC = 0.016–1.5 μg/mL). Ten of 11 iso-
lates with ermB had a 1-bp adenine deletion in
the mtrR promoter. The relationships between
erythromycin MIC, mtrR promoter gene muta-
tion and erm genes are summarized in the Figure.
Two strains without erm genes or mtrR mutations
had low MICs for erythromycin (0.25 and
0.38 μg/mL). Furthermore, the presence of erm
genes in addition to mtrR mutations did not 
increase erythromycin MIC significantly when
compared with each other (p = 0.463).
Serovar distribution
There were 27 serovars among 45 isolates. All
isolates belonged to the serogroup B (WII/III),
but no predominant serovar was noted. Serovars
Bprstuvxy, Botvxy, Btvy, Bvxy, Bty, Bv, and By
were the most common with three isolates in each
serovar. The antimicrobial resistance pattern was
heterogeneous in each serovar.
Discussion
The present study showed a high prevalence of
mtrR promoter deletion (93.3%) and QRDR mu-
tations (84.4%) among 45 N. gonorrhoeae isolates
collected at a university hospital in Southern
Taiwan. Resistance to multiple drugs was present
in 40% of the isolates. The high prevalence of
drug resistance and mutations prohibits the use
Table 2. Minimum inhibitory concentrations of ciprofloxacin for 45 Neisseria gonorrhoeae isolates with or
without mutations in the quinolone-resistance-determining regions
Mutations in QRDR Ciprofloxacin MIC (μg/mL)
gyrA parC Susceptible Intermediate Resistant Total
mutations mutation (≤ 0.06) (0.12–0.5) (≥ 1)
– – – 8 0 0 8
Ser-91Phe – – 0 1 0 1
– Asp-95Asn – 0 1 0 1
Ser-91Phe Asp-95Ala – 0 0 3 3
Ser-91Phe Asp-95Gly – 0 0 3 3
Ser-91Phe Asp-95Gly Ser-87Arg 0 0 21 21
Ser-91Phe Asp-95Ala Ser-87Arg 0 0 3 3
Ser-91Phe Asp-95Ala Ser-87Asn 0 0 3 3
Ser-91Phe Asp-95Ala Glu-91Ala 0 0 1 1
Ser-91Phe Asp-95Gly Asp-86Asn 0 0 1 1
QRDR = Quinolone-resistance-determining regions; MIC = minimum inhibitory concentration; Ser = serine; Phe = phenylalanin; Asp =
aspartic acid; Asn = asparagine; Ala = alanine; Gly = glycine.
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Figure. Minimal inhibitory concentration of erythromycin
for Neisseria gonorrhoeae isolates with a 1-bp adenine
deletion in mtrR promoter loci (n = 31), 1-bp deletion and
erm gene (n = 11), erm gene alone (n = 1), and neither
deletion nor erm gene (n = 2).
of previous first-line antibiotics such as penicillin,
tetracycline, and erythromycin for gonorrhea,
and also limits the choice of highly effective oral
fluoroquinolones and new macrolides, such as
azithromycin, in the endemic area. Our data sup-
ported the treatment guidelines for gonorrhea 
in Taiwan. The regimens recommended by the
Centers for Disease Control, Taiwan include cef-
triaxone and spectinomycin.19 However, decreased
susceptibility to third-generation cephalosporins
among clinical isolates of N. gonorrhoeae has been
documented in some studies.24,25 In a study un-
dertaken in Northern Taiwan, Wong et al demon-
strated that 21.2% and 16.4% of 136 isolates
from male high-risk groups during 2006 and 2007
were resistant to third-generation cephalosporins,
cefpodoxime and cefixime, respectively.26 Third-
generation cephalosporins and spectinomycin are
recommended currently in Taiwan, therefore, on-
going surveillance of antimicrobial resistance is
warranted. Additionally, ceftriaxone and spectin-
omycin are only available as an injection, and have
the disadvantages of inconvenience and possible
needle-stick injury for health care workers. There-
fore, initiation of research for new agents or effi-
cacy of combination antibiotic therapy has been
advocated because drug choice has been limited
in some endemic areas.2
In spite of erythromycin resistance, azithro-
mycin has been considered an alternative treat-
ment for gonococcal diseases,2,27,28 but some
studies have indicated that 1 g azithromycin for
gonorrhea might lead to treatment failure.29,30 In
these studies, MIC of azithromycin for the isolates
was between 0.125 and 0.25 μg/mL, but screen-
ing for mtrR mutation was not undertaken. Al-
though clinical evidence is lacking, azithromycin,
even at a dose of 2 g, which has been an alterna-
tive for uncomplicated urogenital gonococcal 
infections,2,31 should be used very carefully in
the endemic area that has a high possibility of
universal macrolide resistance.
In our study, N. gonorrhoeae isolates that con-
tained an mtrR promoter deletion had higher MICs
for antimicrobial agents. The number of tested
strains was limited and they might have carried
additional resistance genes, therefore, it was dif-
ficult to evaluate the extent of the contribution
of the mtrR mutation to drug resistance. However,
Hogman et al demonstrated that such a mutation
can upregulate the mtr efflux pump. Conse-
quently, its overexpression has been shown to
mediate resistance to macrolides and is related to
decreased susceptibility to penicillin and tetracy-
cline.9,12 In addition, several studies have shown
that clinical gonococcal strains with a 1-bp dele-
tion in the mtrR promoter region have decreased
susceptibility to erythromycin and azithromy-
cin.12–16,32,33 Moreover, it has been speculated
that upregulation of the mtrCDE efflux pump as
a result of mtrR mutation can facilitate transmis-
sion of N. gonorrhoeae, because such strains can re-
sist fecal acids or detergents.34 Some authors have
suggested that strains with the mtr phenotype take
advantage of transmission in the community, and
subsequently acquire more resistance to various
antibiotics.16
QRDR mutations in the present study involved
two codons in gyrA (codons 91 and 95) and three
in parC (codons 86, 87, and 91). The number of
mutations in the QRDR corresponded with the
degree of ciprofloxacin resistance, which was com-
parable with that in previous studies.4–6 More-
over, 84% of our strains carried mutations both
in the QRDR and mtrR loci. A similar finding has
been described in previous studies. Dewi et al re-
ported that simultaneous mutations in the QRDR
and MtrRCDE were observed in 71% of quinolone-
resistant N. gonorrhoeae.16 Although the reason
for this phenomenon is not understood clearly,
it does limit the convenient choice of highly 
effective oral fluoroquinolones and other alter-
native antibiotics, such as azithromycin, in the
endemic area.
The presence of ermA, B, C, and F genes fre-
quently has been associated with macrolide resist-
ance in N. gonorrhoeae strains.8,15,34 Our study
demonstrated that ermA or ermB genes did not
significantly alter erythromycin susceptibility in
N. gonorrhoeae isolates with or without a 1-bp
adenine deletion in the mtrR promoter. Never-
theless, our result suggests the existence of more
QRDR and mtrR mutations in Neisseria gonorrhoeae
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determinant mechanisms in mediating erythro-
mycin resistance among N. gonorrhoeae isolates,
in addition to the erm genes. Currently, there are
eight erm genes that are known to confer mac-
rolide resistance in Neisseria species.8 Moreover,
some other mechanisms, such as mutation in the
peptidyltransferase loop in domain V of the 23S
rRNA alleles or a 153-bp insertion in the mtrR
promoter region, have been shown to cause high
MICs of erythromycin (32–64μg/mL) and azithro-
mycin (4 μg/mL).13,35 Nevertheless, they were un-
likely to have been present in our strains because
our isolates only had MICs of ≤ 6 μg/mL for
erythromycin and ≤ 0.5 μg/mL for azithromycin.
Based on the serotyping results, there were as
many as 27 serovars in our isolates. Serotyping
with monoclonal antibodies is a rapid method,
and has a discriminatory power of > 90%.36,37 Our
results indicated that polyclonal spread of drug-
resistant N. gonorrhoeae strains in the community
was likely to have taken place. However, geno-
typing, such as pulse-field gel electrophoresis, is
necessary for confirmation. Polyclonal spread of
antimicrobial-resistant strains in the community
could compromise drug choice, and be an obsta-
cle for gonorrhea control in public health.
There were limitations in the present study.
First, the tested strains were isolated at a referral
center, and the high prevalence of antimicrobial
resistance could have been the result of selection
bias. Second, the study only screened commonly
reported resistant mechanisms of N. gonorrhoeae.
It was possible that other determinant mecha-
nisms mediated resistance to the various anti-
microbial agents in our isolates. However, the
phenomenon of high prevalence of antimicro-
bial resistance associated with multiple resist-
ance mechanisms in N. gonorrhoeae isolates was
alarming in Southern Taiwan.
In conclusion, the high prevalence of multi-
drug resistance and mutations in the QRDR and
mtrRCDE efflux system could limit the drug
choices for gonorrhea. Furthermore, ongoing sur-
veillance of drug susceptibility and research into
more effective antibiotic regimens for gonorrhea
is warranted in endemic areas.
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